Montreal, Canada
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Canada, with operations in both Montreal and a growing subsidiary in Charlotte, NC. Established in 2007, Milestone is committed to advancing treatments for cardiovascular conditions.
Currently, Milestone is focused on developing etripamil, a novel nasal spray designed for patient-administered termination of PSVT (paroxysmal supraventricular tachycardia) episodes. This product leverages a short-acting calcium channel blocker mechanism, and the company is in Phase 3 clinical trials with plans to explore its efficacy in atrial fibrillation and angina.
The company, listed on Nasdaq with the ticker MIST, received a significant investment of $30.00M in post-IPO equity on 09 February 2024, signaling strong investor confidence. Milestone's innovative approach addresses critical gaps in rapid-onset treatment options for heart rate disorders, positioning it strategically within the Biotechnology, Health Care, and Health and Wellness industries.
